Study of Daratumumab with Dose-Adjusted EPOCH in Newly Diagnosed Plasmablastic Lymphoma
Enrolling By Invitation
18-99 years
All
Phase
N/A
15 participants needed
1 Location
Brief description of study
Patients with plasmablastic lymphoma are potential participants of this research trial. Patients with a type of B-cell non-Hodgkin lymphoma (NHL) will be invited from Penn Medicine practices.
This research study is designed to test the safety of daratumumab, a drug added to the standard lymphoma treatment when given to individuals who have been diagnosed with plasmablastic lymphoma. The hope is that this study treatment may provide a new treatment option for patients with plasmablastic lymphoma, however, such a benefit cannot be guaranteed.
The following are some of the most commonly observed side effects: Fatigue or lack of energy; nausea; diarrhea; shortness of breath; feeling weak; fever; cough; cold-like symptoms (upper respiratory infection); nerve damage causing tingling, numbness, or pain; swollen hands, feet or limbs; constipation. The study drug may also cause serious reactions including: infusion related reaction, changes in blood tests, and decreases in blood cell counts. There is always the possibility that unknown risks and side effects may occur. These may be mild or very serious, and in some cases, may be very serious, long-lasting, or may never go away. There may also be a risk of death.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: lymphoma,cancer
-
Age: Between 18 Years - 99 Years
-
Gender: All
Updated on
22 Aug 2024.
Study ID: 848990
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For cancer trials contact EmergingMed: 1-855-216-0098 or PennCancerTrials@emergingmend.com
